JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 500 from DKK 650 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets
- Notable open interest changes for July 30th
- Novo Nordisk downgraded to Neutral from Buy at BofA
- Novo Nordisk downgraded to Neutral from Outperform at Oddo BHF
- Citi opens ‘upside catalyst watch’ on Eli Lilly post selloff